Durable Response to Immunotherapy Plus Chemotherapy in a Patient With Untreated, Brain-metastatic, EGFR Exon 20 Insertion Mutation Lung Adenocarcinoma

jingying nong  
Xuanwu Hospital  https://orcid.org/0000-0002-0682-2190

Yanfei Gu  
United Family Healthcare

Shuyang Yao  
Xuanwu Hospital

Yi Zhang  (steven9130@sina.com)  
Xuanwu Hospital

Research Article

Keywords: immune checkpoint inhibitors, lung cancer, EGFR rare mutations, brain metastases

DOI: https://doi.org/10.21203/rs.3.rs-415548/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Epidermal growth factor receptor (EGFR) 20 exon insertion is the second most common EGFR aberrations in non-small cell lung cancer (NSCLC). Despite some novel EGFR inhibitors showing encouraging antitumor activity, clinically obtainable management for this subset of patients remains an unmet need. Although immune checkpoint inhibitors (ICIs) have led to unprecedented clinical benefit in metastatic NSCLC, clinical evidence suggests that EGFR mutant lung cancers rarely derive benefit from treatment with ICIs. We report that a lung adenocarcinoma patient harboring an actionable gene mutation of EGFR exon 20 insertion, high PD-L1 expression, high tumor mutational burden, as well as alterations in immune-related genes including CTNNB1 (Catenin β1) S37F and ARID2 (AT-rich interactive domain-containing protein 2) E1056X responded to upfront PD-1 inhibitor plus chemotherapy. As an advanced-stage lung cancer with brain metastases indicating poor prognosis, the patient achieved an unusual and durable response over 15 months. Upfront ICIs plus chemotherapy might be an option for some NSCLC patients harboring EGFR exon 20 insertion mutation. Further study is needed to validate the predictor involved in responders to ICIs-based therapy with EGFR mutations.

Introduction

Programmed cell death-1 (PD-1)/programmed cell death-ligand 1(PD-L1) immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, have revolutionized the standard treatment for non-small-cell lung cancer (NSCLC), bringing unprecedented durable clinical benefit to late-stage patients. Despite this, a portion of patients displays only modest responses or remains unresponsive[1, 2]. Increasing evidence indicates epidermal growth factor receptor (EGFR) mutation to be a negative predictive factor for immunotherapy, with most data explored in classic EGFR mutations 19del and L858R[3, 4], while data in patients harboring EGFR exon 20 insertion mutation are lacking. High-throughput sequencing such as next-generation sequencing could provide more information for treatment selection.

Here we describe a rare case of a lung adenocarcinoma patient with brain metastases (BM) harboring EGFR exon 20 insertion mutation responded to 1st-line PD-1 inhibitor sintilimab plus chemotherapy (pemetrexed and carboplatin), with a continuous partial response both cranial and extra-cranial beyond 1 year.

Case Report

Figure 1 shows the timeline of a 56-year-old man who sought care for dry cough that had been progressively worsening over 4 weeks, he was neurologically asymptomatic and had tobacco use of 1 pack x 20 years. A computed tomographic scan revealed a large mass in the left lower lobe of the lung. Magnetic resonance imaging (MRI) of the head revealed numerous tumor lesions, with mass effect and local edema. A core biopsy specimen of the left lower lobe mass showed lung adenocarcinoma that was positive for cytokeratin 7 ( CK7), negative for cytokeratin 20 ( CK20), and positive for thyroid transcription
factor 1 (TTF1) on immunoperoxidase staining. The PD-L1 (SP263) testing showed high expression with a tumor proportion score of 90% (figure 2A).

Molecular testing on the biopsied tissue via next-generation sequencing (NGS) revealed an \textit{EGFR} exon 20 in-frame insertion (P772\_H773insYNP+H773Y), Microsatellite stability (MS), and high tumor mutational burden (TMB) 10.5 Mut/Mb. Also, alterations in immune-related genes were revealed including \textit{CTNNB1} (Catenin \(\beta\) 1) S37F, and \textit{ARID2} (AT-rich interactive domain-containing protein 2) E1056X, with some variants of unknown significance (figure 2B).

The patient started treatment of chemotherapy (pemetrexed and carboplatin(CBP)) plus PD-1 inhibitor sintilimab in November 2019. After 4 cycles of treatment, the patient achieved a partial response per Response Evaluation Criteria In Solid Tumors, Version 1.1, with a decrease in lung mass, and the brain tumors shrunk continuously. After 6 cycles of treatment, the patient then accepted sintilimab plus pemetrexed every 3 weeks as maintenance therapy, which was well-tolerated without any toxicity and is still ongoing after 15 months since initiation of 1st-line treatment.

Follow-up imaging, by brain MRI, chest, abdominal, pelvic CT, and bone-scan at various time points showed a continuous decrease in the size of both the lung and brain lesions, with no new sites of disease. At a follow-up of 15 months after diagnosis, the patient continued to take pemetrexed plus PD-1 inhibitor, without evidence of progressive disease at last follow-up.

**Discussion**

\textit{EGFR} mutations are detected in 20\%~50\% of lung adenocarcinoma patients, \textit{EGFR} exon 20 insertions are the next most common \textit{EGFR} mutations in NSCLC after classical mutations, accounting for 4-10\% of all observed \textit{EGFR} aberration[5, 6]. Most \textit{EGFR} exon 20 insertion mutations predict resistance to clinically achievable levels of tyrosine kinase inhibitors (TKIs) in advanced NSCLC, although there are rare exceptions. Some novel EGFR inhibitors have shown encouraging antitumor activity for \textit{EGFR} exon 20 insertions[7], but commercially obtainable effective targeted drugs remain an unmet need in clinical management. Therefore, platinum-based chemotherapy is considered standard treatment for these patients.

This patient harbored \textit{EGFR} exon 20 in-frame insertion (P772\_H773insYNP+H773Y). exon 20 H773Y was previously detected combined with exon 20 insertions[6, 8]. Preclinical research indicated that the complex mutations of exon 20 insertion combined with H773Y resist 1st-generation EGFR-TKIs[8], while clinical evidence for the effect of 2nd or 3rd generation EGFR-TKIs are lacking.

Although ICIs have revolutionized the systemic treatment of patients of NSCLC with \textit{EGFR} wild-type (WT), the activity and clinical impact in the subgroup of \textit{EGFR} mutation-positive tumors have been lower than in the \textit{EGFR}WT population in large 2nd- and 3rd-line phase III trials and 1st-line trials evaluating the efficacy of ICIs often excluded \textit{EGFR}-mutation-positive patients. Anecdotal evidence suggests that some \textit{EGFR} mutation-positive patients benefit from PD-1/PD-L1 inhibitors[9]. \textit{EGFR} exon 20 mutations demonstrated...
a higher response rate and longer survival compared to classic EGFR mutations[10]. A case report
demonstrated that a heavily pre-treated patient of NSCLC with EGFR exon 20 insertion mutation
responded to ICIs-based therapy[11]. But the effect of upfront ICIs in lung cancer patients harboring EGFR
exon 20 insertion mutation is lacking. This patient had high PD-L1 expression, PD-L1 is a positive
predictive biomarker of ICIs, which has been prospectively validated and approved by the Food and Drug
Administration (FDA), and was also positively associated with outcomes for ICIs in EGFR mutant
NSCLC[4].

Considering this patient was neurologically asymptomatic, with rare EGFR mutations, high PD-L1
expression, and High TMB[12], therefore, 1st-line immunotherapy plus chemotherapy was applied. A
durable response was achieved with impressive control in both extra-cranial and cranial tumor lesions.

Brain metastases, associated with poor clinical outcomes, are diagnosed in approximately 20% of NSCLC
patients[13]. For asymptomatic BM, upfront systemic chemotherapy could be an option. However,
traditional chemotherapy drugs have a limited role in BM management, owing to the presence of efflux
pumps[14, 15], and lacking penetration of the blood-brain barrier (BBB). Here is the rational basis for ICIs-
based treatment in patients with BM: first, antitumor T cells are activated and home to the brain from
extra-cranial sites, second, tumor neo-vessels are leaky to facilitate ICIs penetrating to stimulate tumor-
associated T cells. Prospective trials evaluating ICIs efficacy in previously untreated BM are scarce. It was
supported by a few studies of anti-PD-1 mono-therapy that ICIs can induce intra-cranial response[16, 17],
[18]. Series of retrospective studies provided evidence that intracranial and extra-cranial ICIs efficacy are
comparable [16, 19].

Some questions have yet to be resolved regarding how to identify the patients most likely to benefit from
ICIs-based therapy, and how to weigh the probability of immunotherapy benefit when concomitant
potential positive and negative factors both exist. For this patient, concomitant alterations in immune-
related genes were revealed including CTNNB1 S37F and ARID2 E1056X. CTNNB1 S37F is a gain-of-
function mutation that could lead to aberrant activation of the WNT/β-catenin signaling, which is
enriched in non-T cell inflamed tumors[20] [21] and has been linked to lack of benefit of immunotherapy
in NSCLC[22]. Whereas, ARID2 E1056X is a loss-of-function mutation. ARID2, encoding a PBAF complex
subunit, acts as an immunomodulator. ARID2 mutation is a potential biomarker positively indicating ICIs
effectiveness in melanoma patients[23-25]. Considering that biomarkers are often complex and non-
binary, and we only see part of the picture since the potential heterogeneity has not been evaluated,
therefore, it is overly simplistic to seek predictive power from a single marker. An interconnected network
of multiple factors would be the eventual biomarker to form a more complete puzzle.

In conclusion, our case demonstrated that upfront chemotherapy plus PD-1 inhibitor might be an option
for some NSCLC patients of BM harboring EGFR exon 20 insertion and high PD-L1 expression/high TMB.
Additional insights into gene aberrations provide more information. Further study is needed to validate
the predictor involved in responders to ICIs-based therapy with EGFR mutations.
Declarations

Funding: The authors did not receive any funding for this study.

Conflict of interest: The authors have no conflicts of interest to declare under consideration for publication.

Availability of data and material: All data generated or analyses of this case were included in this published report.

Ethics approval and consent to participate: The patient gave his oral and written informed consent. The case report was approved by the Ethics Committee (Medical Research Ethics Committee of Xuanwu Hospital).

Consent for publication: the patient has signed a consent for publication.

Informed consent: Waived by the Institutional review board because of the retrospective nature of this case report.

Acknowledgement: We thank the patient and families.

Authors’ contributions: NJY designed the study and wrote the initial draft of the manuscript. GYF assisted in the preparation of the manuscript. All other authors have contributed to review the manuscript. All authors approved the version of the manuscript finally and agree to be accountable for all aspects of the work.

References

1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015, 373(2):123-135.doi:10.1056/NEJMoa1504627

2. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016, 387(10027):1540-1550.doi:10.1016/S0140-6736(15)01281-7

3. Takada K, Toyokawa G, Tagawa T, Kohashi K, Shimokawa M, Akamine T, Takamori S, Hirai F, Shoji F, Okamoto T: PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer 2018, 116:1

4. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R et al: Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019, 30(8):1321-1328.doi:10.1093/annonc/mdz167
5. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M: EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. *Mol Cancer Ther* 2013, 12(2):220-229

6. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I *et al.*: Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. *Proc Natl Acad Sci U S A* 2019, 116(20):10025-10030. doi:10.1073/pnas.1819430116

7. Remon J, Hendriks LEL, Cardona AF, Besse B: Anti-tumour Treatment EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. *Cancer Treat Rev* 2020, 90

8. Chi-Hsien C, Gow C-H, Chong-Jen Y, Shih J-Y, Ya-Chieh H, Wen-Yu L, Pan-Chyr Y, Kuo S-H: Clinical Response of Gefitinib on Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer. *Journal of Cancer Molecules* 2008, 4

9. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC: Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. *Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology* 2018, 36(17):JCO2017770412

10. Negrao MV, Reuben A, Robichaux JP, Le X, Heymach J: Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. *J Clin Oncol* 2018, 36(15_suppl):9052-9052

11. Huang X, Yang Y, Wang P, Han-Zhang H, Ding L: A heavily pre-treated adenocarcinoma patient with EGFR exon 20 insertion mutation responded to pembrolizumab plus nab-paclitaxel/bevacizumab: a case report. *Ann Palliat Med* 2020. doi:10.21037/apm-20-1307

12. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F *et al.*: First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *N Engl J Med* 2017, 376(25):2415-2426. doi:10.1056/NEJMoa1613493

13. Barnholtz-Sloan, J. S: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol* 2004, 22(14):2865-2872

14. Eichler AF, Chung E, Kodack DP, Loeffer JS, Fukumura D, Jain RK: The biology of brain metastases—translation to new therapies. *Nature Reviews Clinical Oncology* 2011, 8(6):344-356

15. Fortin D: The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases. *Curr Cancer Drug Targets* 2012, 12(3):-

16. Dudnik E, Yust-Katz S, Nechushtan H, Goldstein DA, a AZ, a DF, e TSb, f NPa: Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases - ScienceDirect. *Lung Cancer* 2016, 98(4 Suppl):114-117

17. None: Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. *Ann Oncol* 2016
18. Goldman JW, Crino L, Vokes EE, Holgado E, Brahmer JR: Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). *J Clin Oncol* 2016, 34(15_suppl):9038-9038

19. Watanabe H, Kubo T, Ninomiya T, Ohashi K, Kiura K: The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. *J Clin Oncol* 2017, 35(15_suppl):e20601-e20601

20. Spranger S, Bao R, Gajewski TF: Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. *Nature* 2015, 523(7559):231-235.doi:10.1038/nature14404

21. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF: WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. *Clin Cancer Res* 2019, 25(10):3074-3083.doi:10.1158/1078-0432.CCR-18-1942

22. Montana FJR, Iranzo P, Pedrola A, Callejo A, Felip E: 1989PWNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients. *Ann Oncol* 2019, 30(Supplement_5)

23. Deng P, Aya K, Peng J, Lucas FDA, Rong En T, Luoma AM, Daphne T, Xintao Q, Klothilda L, Prakash R: A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing. *Science* 2018, 359(6377):770-775

24. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D: Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* 2018:eaan5951

25. Fukumoto T, Lin J, Fatkhutdinov N, Liu P, Somasundaram R, Herlyn M, Zhang R, Nishigori C: ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. *J Invest Dermatol* 2020.doi:10.1016/j.jid.2020.11.026

Figures
Figure 1

Timeline of clinical response. Shown is the timeline of cranial and extra-cranial clinical response of the NSCLC patient with EGFR 20 exon insertion mutant to 1st-line PD-1 inhibitor plus chemotherapy. The evolution of the disease was demonstrated by brain MRI and chest CT at various time points. NGS analyses were performed at the time of diagnosis (October 2019). Sintilimab plus chemotherapy (pemetrexed+CBP) were initially provided for 6 cycles, followed by Sintilimab plus pemetrexed as maintenance therapy.
Figure 2

Histopathologic analyses and Molecular detection by NGS at diagnosis. (A) Histopathologic analyses at diagnosis. (upper left) CT imaging shows the biopsy site (arrowhead) at the left lower lobe mass of the lung. (lower left) Low-power magnification (Original magnification, 10x) shows lung biopsy widely infiltrated by adenocarcinomatous architecture. (upper right) high-power magnification (Original magnification, 40x) shows neoplastic cells with abundant pale eosinophilic cytoplasm and atypical round to oval nuclei. (lower right) 90% of these neoplastic cells express PD-L1. (B) Molecular alterations of lung biopsy by NGS at diagnosis.